ASCO 2014

Well after a week in Chicago I had a great time at the American Society of Clinical Oncology (ASCO) conference. I did this write up on my site:

advancedpcatalk.freeforums.net/thread/122/asco-2014-event-good-pca

I mentioned what I felt were the biggest things I took home about PCa. But there were so many other things to bring home that I will be writing about them over the next few weeks after studying them. The poster sessions were great as we had S1216 introduced. As noted before that is a trial comparing ADT with LHRH Agonists in both arms but one arm was standard of care with bicalutamide and the test arm was with TAK-700. Agarwal et al, are showing great accrual for the trial but nothing to report. That trial is dear to me as I am a co-author of that paper.

Poster of S1216
/drive.google.com/file/d/0B_t9_NUAIqFdUkxCS3VvVGFLTjg/edit?usp=sharing

Abstract of S1216
abstracts.asco.org/144/AbstView_144_130445.html

Again the most significant evets for prostate cancer are in the first link above. Item #3 concerns me deeply. The NCI has lost 25% of it's budget and this after the last 8 years of a flatline budget that never saw a rise in research funding. That will definitely be a bad thing into the future and if you get the chance, please write your congressional leaders about it. Cancer research has always been a strong suit of American Medicine and that will probably change if cancer research is no longer the priority it was.

Lastly, and on a funny note, My badge had my name as Anthony instead of Tony. All my friends were having fun after I told them the only time I was ever called Anthony was when I was in trouble. Maha Hussain (UMich) said then she now knows how to handle me. David Quinn (USC) said it would have looked better in the presentation that Tony. I asked why, he said it would have taken more space on the poster. Geez...He's right darn it!

Tony, Thanks for the report and all that you do!

I think the last paragraph in this article emphasizes one significant importance of NCI www.onclive.com/conference-coverage/asco-2014/Upfront-Chemo-Confers-Dramatic-Survival-Gains-in-Prostate-Cancer.

I'm pleased to be directly involved with NIH/NCI and have been a part of 3 NCI supported studies thus far; came off a promising trial Xtandi wProstvac trial www.clinicaltrials.gov/ct2/show/NCT01867333 and currently on Docetaxel w/XL184 (cabozantinib) clinicaltrials.gov/ct2/show/NCT01683994 and am also supporting the “Pilot Study of Eovist (Gadoxetate) Enhanced MRI for the Detection of Prostate Cancer." clinicaltrials.gov/ct2/show/NCT01867424 (imaging is completed, biopsy next week).

I can tell you first hand that the folks who work there are proud of what they do and they do need all of our support. Please do write your congressional leaders as Tony suggests.